Medidata, a provider of cloud-based technology and data analytics for clinical research, and Syapse, a precision medicine solutions provider, have announced a new partnership to transform oncology clinical trials for the age of precision medicine. As part of the new partnership, Medidata and Syapse will jointly develop a portfolio of solutions to make it easier for cancer patients to access potentially life-saving clinical trials,
The partnership will initially build products to assist trial sponsors in designing eligibility criteria, identify community health systems as trial sites, and enable oncologists and their care teams to easily identify patients for enrollment into cutting-edge clinical trials.
Medidata’s solutions power clinical trials for 18 of the world’s top 25 pharmaceutical companies, and Syapse solutions power precision medicine for nearly 300 hospitals across 25 states. The partnership aims to bring these products to pharmaceutical companies and health systems at scale over the coming years.
In 2017, the approval of novel drugs in the U.S. hit a 21-year high, with many targeting rare diseases and types of cancer. The continued growth of precision medicine compounds the challenges of finding the right patients for the right trials in oncology. This approach segments populations based on both traditional clinical factors and novel molecular characteristics, thus reducing population sizes for targeted therapy and immunotherapy trials.
“Syapse and Medidata are coming together to democratize access to clinical trials for patients across the country,” said Ken Tarkoff, CEO of Syapse in a statemnet. “The many targeted cancer therapies in development today can save patients’ lives, but only if we improve clinical trials so they reach the patients who can benefit from them. Syapse and Medidata are uniquely positioned to tackle this problem, at an unparalleled scale, because of our combined partnerships with community health systems and life sciences companies.”